Literature DB >> 10589997

Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion.

A Puri1, P Hug, K Jernigan, P Rose, R Blumenthal.   

Abstract

We have recently shown that addition of human erythrocyte glycosphingolipids (GSL) to non-human CD4+ or GSL-depleted human CD4+ cells rendered those cells susceptible to gp120-gp41-mediated cell fusion (Puri et al., BBRC, 1998). One GSL fraction (Fraction 3) isolated from human erythrocyte GSL mixture exhibited the highest recovery of fusion following incorporation into CD4+ non-human and GSL-depleted HeLa-CD4 cells (HeLa-CD4/GSL-). Structural analysis of Fraction 3 showed that this GSL had identical head group as the known GSL, Gal(alpha1-->4)Gal(beta1-->4)Glc-Ceramide (Gb3) (Puri et al., PNAS, 1998). Here we report that presence of Gb3 in CD4+/CXCR4+ cells but not CD4+/CXCR4 cells allows fusion with HIV-1Lai-envelope glycoprotein expressing cells (TF228). Therefore, Gb3 functions in conjunction with HIV-1 co-receptor, CXCR4 to promote fusion. We propose that Gb3 functions by recruiting CD4 and/or CXCR4 at the fusion site through structurally specific interactions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589997     DOI: 10.1023/a:1020554509642

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  11 in total

1.  Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane.

Authors:  Ruben M Markosyan; Fredric S Cohen; Grigory B Melikyan
Journal:  Mol Biol Cell       Date:  2005-09-29       Impact factor: 4.138

Review 2.  Role of glycosphingolipids in dendritic cell-mediated HIV-1 trans-infection.

Authors:  Wendy Blay Puryear; Suryaram Gummuluru
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

3.  Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion.

Authors:  J Fantini; D Hammache; G Piéroni; N Yahi
Journal:  Glycoconj J       Date:  2000 Mar-Apr       Impact factor: 2.916

4.  Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.

Authors:  Andrew Rosa Borges; Lindsay Wieczorek; Benitra Johnson; Alan J Benesi; Bruce K Brown; Richard D Kensinger; Fred C Krebs; Brian Wigdahl; Robert Blumenthal; Anu Puri; Francine E McCutchan; Deborah L Birx; Victoria R Polonis; Cara-Lynne Schengrund
Journal:  Virology       Date:  2010-09-28       Impact factor: 3.616

Review 5.  Blood Groups in Infection and Host Susceptibility.

Authors:  Laura Cooling
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

6.  Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5.

Authors:  P Hug; H M Lin; T Korte; X Xiao; D S Dimitrov; J M Wang; A Puri; R Blumenthal
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells.

Authors:  K A Weigel-Kelley; M C Yoder; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection.

Authors:  Richard D Kensinger; Bradley J Catalone; Fred C Krebs; Brian Wigdahl; Cara-Lynne Schengrund
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Progressive truncations C terminal to the membrane-spanning domain of simian immunodeficiency virus Env reduce fusogenicity and increase concentration dependence of Env for fusion.

Authors:  Xiaoxu Lin; Cynthia A Derdeyn; Robert Blumenthal; John West; Eric Hunter
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 10.  Ceramide and Related Molecules in Viral Infections.

Authors:  Nadine Beckmann; Katrin Anne Becker
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.